Chen L, Dai Z, Song H, Zhang J, Li T
Front Pharmacol. 2024; 15:1473756.
PMID: 39575385
PMC: 11578700.
DOI: 10.3389/fphar.2024.1473756.
Marina D, Ejersted C, Hommel K, Schwarz P
Arch Endocrinol Metab. 2024; 68:e240159.
PMID: 39529985
PMC: 11554369.
DOI: 10.20945/2359-4292-2024-0159.
Mohamed R, Abdelrahim D, Hay N, Fawzy N, M D, Yehia D
Sci Rep. 2024; 14(1):18283.
PMID: 39112499
PMC: 11306734.
DOI: 10.1038/s41598-024-68303-z.
Ma Y, Xu S, Xu Z, Zhang Y, Lu C, Chen D
Endocrine. 2023; 83(2):459-465.
PMID: 37971631
DOI: 10.1007/s12020-023-03567-5.
Moody M, Schmidt T, Trivedi R, Deymier A
PLoS One. 2023; 18(9):e0291649.
PMID: 37713420
PMC: 10503749.
DOI: 10.1371/journal.pone.0291649.
A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer.
Li W, Wu X, Yu H, Zhu Z, Li W, Huang X
Clin Med Insights Oncol. 2023; 17:11795549231182266.
PMID: 37448470
PMC: 10336762.
DOI: 10.1177/11795549231182266.
Fecal incontinence as the sole presentation of focal epilepsy; a case report.
Al-Ameri L, Hameed E, Maroof B, Al-Momen H
Oxf Med Case Reports. 2023; 2023(6):omad064.
PMID: 37377719
PMC: 10292643.
DOI: 10.1093/omcr/omad064.
Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis.
Lorange J, Ramirez Garcia Luna J, Grou-Boileau F, Rosenzweig D, Weber M, Akoury E
J Bone Oncol. 2023; 39:100470.
PMID: 36860585
PMC: 9969300.
DOI: 10.1016/j.jbo.2023.100470.
Treatment of Diabetes and Osteoporosis-A Reciprocal Risk?.
Zawada A, Ratajczak A, Rychter A, Szymczak-Tomczak A, Dobrowolska A, Krela-Kazmierczak I
Biomedicines. 2022; 10(9).
PMID: 36140292
PMC: 9495959.
DOI: 10.3390/biomedicines10092191.
Renal safety of zoledronic acid for osteoporosis in adults 75 years and older.
Fixen C, Fixen D
Osteoporos Int. 2022; 33(11):2417-2422.
PMID: 35829757
DOI: 10.1007/s00198-022-06499-4.
Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self-Controlled Case Series in the United Kingdom.
Oda T, Jodicke A, Robinson D, Delmestri A, Keogh R, Prieto-Alhambra D
J Bone Miner Res. 2022; 37(7):1270-1278.
PMID: 35579494
PMC: 9543096.
DOI: 10.1002/jbmr.4573.
The Challenges of Diagnosing Nondilated Obstructive Uropathy: A Case Report.
Shahzad M, Baxi P, Rodby R
Can J Kidney Health Dis. 2022; 9:20543581221086683.
PMID: 35356536
PMC: 8958704.
DOI: 10.1177/20543581221086683.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
Mollica V, Nuvola G, Tassinari E, Nigro M, Marchetti A, Rosellini M
Curr Oncol. 2022; 29(3):1709-1722.
PMID: 35323342
PMC: 8947753.
DOI: 10.3390/curroncol29030142.
The role of bone-modifying agents in myeloma bone disease.
Lu H, Pundole X, Lee H
JBMR Plus. 2021; 5(8):e10518.
PMID: 34368608
PMC: 8328802.
DOI: 10.1002/jbm4.10518.
Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid Administration to Dogs With Malignant Osteolysis.
Vidal S, Skorupski K, Willcox J, Palm C, Burton J
Front Vet Sci. 2021; 8:647846.
PMID: 34277751
PMC: 8282816.
DOI: 10.3389/fvets.2021.647846.
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Jiang L, Cui X, Ma H, Tang X
J Orthop Surg Res. 2021; 16(1):400.
PMID: 34158101
PMC: 8218501.
DOI: 10.1186/s13018-021-02554-8.
Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
Robinson D, Ali M, Strauss V, Elhussein L, Abrahamsen B, Arden N
Health Technol Assess. 2021; 25(17):1-106.
PMID: 33739919
PMC: 8020200.
DOI: 10.3310/hta25170.
Bisphosphonate nephropathy: A case series and review of the literature.
de Roij van Zuijdewijn C, van Dorp W, Florquin S, Roelofs J, Verburgh K
Br J Clin Pharmacol. 2021; 87(9):3485-3491.
PMID: 33595131
PMC: 8451932.
DOI: 10.1111/bcp.14780.
Characterization of the small molecule ARC39, a direct and specific inhibitor of acid sphingomyelinase in vitro.
Naser E, Kadow S, Schumacher F, Mohamed Z, Kappe C, Hessler G
J Lipid Res. 2020; 61(6):896-910.
PMID: 32156719
PMC: 7269768.
DOI: 10.1194/jlr.RA120000682.
Bone-targeted agents in multiple myeloma.
Nishida H
Hematol Rep. 2018; 10(1):7401.
PMID: 29721251
PMC: 5907643.
DOI: 10.4081/hr.2018.7401.
